Managing Amyloidosis in 2024: Diagnosis and Treatment

Indy Hematology Review

M. Gertz

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…

Scripps Health

M. Gertz

POEMS Syndrome Management

MyCancerHaven

R. Vij, D. Dingli

Lung Involvement in Amyloidosis

Houston Methodist

H. Huang

Key Myeloma & MGUS Updates From ASH

Memorial Sloan Kettering Cancer Center

S. Mailankody

Experts Discuss the Management of Monoclonal Gammopathy of Renal Sig…

MyCancerHaven

R. Vij, N. Leung

Management of AL Amyloidosis

GRACE

S. Rajeeve

Updates on AL Amyloidosis Treatment: What’s New in 2024

Dana-Farber Cancer Institute

G. Bianchi

Why We Should Not Treat SMM

PleXus Communications

B. Derman

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Indy Hematology Review

M. Gertz

"You Have AL-Amyloidosis": Counseling Newly Diagnosed Patients

Morie Gertz

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy & Safe…

Insights from 2023 ASH Annual Meeting

O. Landgren

Treating Amyloidosis in 2024

MyCancerHaven

R. Vij, J. Zonder

AL Amyloidosis Treatment Updates

Yale Cancer Center

T. Parker

Emerging and Current Treatment of MM: What Should We Know and What S…

Indy Hematology Review

K. Anderson

Overview of Pathophysiology, Diagnosis and Management of Multiple My…

University of Colorado Division of Hematology

K. Sidor

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Yale Cancer Center

A. Chari